1. LINE

      Text:AAAPrint
      Sci-tech

      Australia begins production of Oxford-developed COVID-19 vaccine

      1
      2020-11-09 10:48:40Xinhua Editor : Cheng Zizhuo ECNS App Download
      Special: Battle Against Novel Coronavirus

      Australia commenced locally manufacturing a COVID-19 vaccine candidate developed by the University of Oxford from Monday, with roughly 30 million doses planned to be made.

      Despite still undergoing clinical trials, the vaccine, which was co-developed by pharmaceutical company AstraZeneca, is considered one of the more promising vaccines globally.

      Australian biotech firm CSL has agreements with AstraZeneca and the Australian government to begin pre-emptive production of the vaccine, for release during the first half of 2021 should remaining tests prove successful.

      "We are undertaking these manufacturing activities at-risk and in parallel with the clinical trials and approvals processes in recognition of the significant urgency of the COVID-19 pandemic," CSL's Chief Scientific Officer Andrew Nash said.

      It is expected the vaccine will require a two-dose per person regime meaning it could be effectively administered to 15 million people. However, it will not be released for use until the development process is reviewed and approved by Australia's government regulatory authority, the Therapeutic Goods Administration (TGA).

      Production will take place at CSL's bioreactor facility in the State of Victoria, with the manufacturing process beginning by thawing vials containing vaccine cells which had been frozen under liquid nitrogen.

      "After growing in the bioreactors, the vaccine is then filtered and purified leaving just the antigen, or vaccine product. It is then ready for final formulation and filling into dosage vials," the company said in a statement.

      CSL had already manufactured several doses of another COVID-19 vaccine candidate developed by Australia's University of Queensland (UQ), which it is holding in readiness to progress to Phase 2b/3 clinical trials.

      Further trials on the UQ vaccine candidate are due pending the release and review of Phase 1 clinical trial data.

      MorePhoto

      Most popular in 24h

      MoreTop news

      MoreVideo

      LINE
      Back to top Links | About Us | Jobs | Contact Us | Privacy Policy
      Copyright ©1999-2020 Chinanews.com. All rights reserved.
      Reproduction in whole or in part without permission is prohibited.
      主站蜘蛛池模板: 国产va免费观看| 成人免费视频77777| 免费一级肉体全黄毛片| 亚洲老熟女五十路老熟女bbw| 97在线线免费观看视频在线观看| 亚洲免费在线视频观看| 国产精品免费观看久久| 亚洲熟妇丰满xxxxx| 日本道免费精品一区二区| 免费观看男人免费桶女人视频| 学生妹亚洲一区二区| 免费看大黄高清网站视频在线| 久久亚洲精品成人无码| 亚洲国产精品嫩草影院久久| a级毛片毛片免费观看久潮| 亚洲国产精品线在线观看| 中文字幕免费高清视频| 亚洲色无码专区一区| 亚洲成年人啊啊aa在线观看| 两个人看www免费视频| 亚洲国产精品美女| 无码国产精品一区二区免费vr| 四虎免费永久在线播放| 亚洲a∨无码精品色午夜| 亚洲成网777777国产精品| 嫩草影院在线播放www免费观看| 亚洲最大视频网站| 亚洲成a人片在线播放| 男人进去女人爽免费视频国产| 国产亚洲国产bv网站在线| 成人亚洲综合天堂| 亚洲AV无码AV男人的天堂不卡| 国产亚洲精品激情都市| 91福利视频免费| 特级毛片A级毛片免费播放| 亚洲国产精品久久| 无码欧精品亚洲日韩一区夜夜嗨 | 在线观看日本亚洲一区| 久99精品视频在线观看婷亚洲片国产一区一级在线 | 国产综合精品久久亚洲| 1000部免费啪啪十八未年禁止观看|